Acalabrutinib
- Generic Name
- Acalabrutinib
- Brand Names
- Calquence
- Drug Type
- Small Molecule
- Chemical Formula
- C26H23N7O2
- CAS Number
- 1420477-60-6
- Unique Ingredient Identifier
- I42748ELQW
- Background
To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others.
...
- Indication
Acalabrutinib is currently indicated for the treatment of adult patients with Mantle Cell Lymphoma (MCL) who have received at least one prior therapy. It has also been recently approved for chronic lymphocytic leukemia and small lymphocytic lymphoma.
- Associated Conditions
- Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma (MCL), Small Lymphocytic Lymphoma
- Associated Therapies
- -
Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure
- Conditions
- Interventions
- First Posted Date
- 2024-10-22
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 60
- Registration Number
- NCT06651970
- Locations
- 🇬🇧
Research Site, Sutton Coldfield, United Kingdom
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
- First Posted Date
- 2024-08-21
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 180
- Registration Number
- NCT06564038
Efficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL
- Conditions
- Interventions
- First Posted Date
- 2024-06-04
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 152
- Registration Number
- NCT06441097
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
- Conditions
- Interventions
- First Posted Date
- 2024-05-24
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 120
- Registration Number
- NCT06428019
- Locations
- 🇺🇸
Springfield Clinic /ID# 270145, Springfield, Illinois, United States
🇺🇸Oklahoma Cancer Specialists and Research Institute /ID# 267643, Tulsa, Oklahoma, United States
🇫🇷Centre Hospitalier de la Côte Basque /ID# 266847, Bayonne, Pyrenees-Atlantiques, France
A Global Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.
- Conditions
- Interventions
- First Posted Date
- 2024-03-20
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- Ascentage Pharma Group Inc.
- Target Recruit Count
- 344
- Registration Number
- NCT06319456
- Locations
- 🇨🇳
Henan Provincial Cancer Hospital, Zhengzhou, Henan, China
🇨🇳Hematology Hospital of the Chinese Academy of Medical Sciences, Tianjin, Tianjin, China
🇨🇳The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
Acalabrutinib Real World Italian obSErvational Study -ARISE
- Conditions
- First Posted Date
- 2024-01-16
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 190
- Registration Number
- NCT06205498
- Locations
- 🇮🇹
Research Site, Viterbo, Italy
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
- Conditions
- Interventions
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1200
- Registration Number
- NCT06136559
- Locations
- 🇨🇿
Vseobecna fakultni nemocnice v Praze-I. Interní klinika - klinika hematologie ( Site 0302), Praha 2, Czechia
🇲🇾Queen Elizabeth Hospital ( Site 1603), Kota Kinabalu, Sabah, Malaysia
🇲🇽Centro de Infusion Superare ( Site 2602), Ciudad de México, Distrito Federal, Mexico
Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2023-09-26
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 40
- Registration Number
- NCT06054776
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2023-07-19
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 108
- Registration Number
- NCT05951959
- Locations
- 🇬🇧
Research Site, Plymouth, United Kingdom
Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL
- Conditions
- Interventions
- First Posted Date
- 2023-07-19
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 80
- Registration Number
- NCT05952024
- Locations
- 🇵🇷
Research Site, San Juan, Puerto Rico
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.